Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways
What this study shows
Shows IGF-1 drives muscle fiber hypertrophy through Akt, via both the mTOR and GSK3 branches, in cultured myotubes, establishing mTOR as a central node for muscle growth signaling.
At a glance
| Evidence type | M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Cultured muscle cells (mouse)) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is. |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | Cultured muscle cells (mouse) |
| Journal | Nature Cell Biology |
| Year | 2001 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1038/ncb1101-1009 · PMID 11715022 |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | IGF-1 |
| Target | PI3K/Akt/mTOR & Akt/GSK3 |
| Model | Cultured muscle cells (mouse) |
| Effect | IGF-1 drives skeletal myotube hypertrophy via PI3K/Akt/mTOR and PI3K/Akt/GSK3 pathways |
In the Atlas
Related topics
Links in the pathway map
- Supports Growth hormone / IGF-1 axis activates PI3K
- Supports Protein synthesis activates Muscle growth
Open questions that cite this study
- Cited as supporting evidence for the open question Muscle-sparing, pulsed mTORC1 inhibition.
More studies on this topic
- Feeding-Induced Muscle mTORC1 Signaling Regulates Postprandial Protein Synthesis and Endurance but Not Muscle Size (2026)
- Strengthening Muscle for Healthy Ageing: Innovative Treatments for Sarcopenia (2026)
- Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesis (2009)
- Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results (2025)
Was this page useful?
Thank you. Your answer was counted anonymously.